INSIGHTS ON CELL & GENE MANUFACTURING AND LOGISTICS

• Pioneering The First Cell Therapy For Solid Tumors

  I spoke to Iovance Biotherapeutics to learn about the company's preparation leading up to the approval of Amtagvi, the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy aimed at treating solid tumors.

• Advantages Of Cas9 mRNA For Gene Editing

  Discover why Cas9 mRNA is the preferred choice for precise gene editing, offering efficient delivery, transient expression, and flexible targeting.

• mRNA: The Fourth Pillar Of Pharmaceutical Innovation And Intervention

  mRNA medicines represent the genesis of a fourth pillar of pharma innovation. While exciting, there are several critical challenges we must solve to strengthen this pillar, including stability and deliverability.

• Bringing CGTs To Middle Income, Developing Countries

  In this segment from the Cell & Gene Live digital event Stem-Cell Derived Therapies: From Source To Site, panelists take an optimistic look at the future promise of bringing CGTs to patients.

• Intermediate Storage For Cell Therapies

  This segment from the Cell & Gene Live digital event explores intermediate storage options for cell therapy products and the factors to consider when working with these vendors.

• The Importance Of Mock Runs, Testing Your Processes

  Panelists in this Cell & Gene Live digital event discuss the importance of performing mock runs to pressure test your processes and operations before sending out a commercial product.

• Selecting The Right Vendors When Building Your Supply Chain

  What factors should you consider when looking for supply chain vendors?

• Are There Genetic Risks To Patients When Using Pooled Donor Manufacturing?

  This segment from the Cell & Gene Live digital event Stem-Cell Derived Therapies: From Source To Site, delves into the potential risk to patients when transplanting pooled allogeneic stem cells.

• The Challenges With Shipping Cell Therapy Products

  In this Cell & Gene Live digital event Stem-Cell Derived Therapies: From Source To Site segment, panelists share some of the worst-case shipping scenarios they’ve encountered when transporting cellular products.

• The Need For Improved Cryoprotectants

  Cryoprotectants are added chemicals or media that protect cells during freezing and thawing — and until we can lyophilize cells, they’re our best bet at preserving cell therapies for storage.